학술논문
Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada
Document Type
article
Author
Jeffrey T. Ha; Anish Scaria; Jason Andrade; Sunil V. Badve; Peter Birks; Sarah E. Bota; Anna Campain; Ognjenka Djurdjev; Amit X. Garg; Ziv Harel; Brenda Hemmelgarn; Carinna Hockham; Matthew T. James; Meg J. Jardine; Dickson Lam; Adeera Levin; Eric McArthur; Pietro Ravani; Selena Shao; Manish M. Sood; Zhi Tan; Navdeep Tangri; Reid Whitlock; Martin Gallagher; Min Jun
Source
Kidney Medicine, Vol 5, Iss 7, Pp 100675- (2023)
Subject
Language
English
ISSN
2590-0595
Abstract
Rationale & Objective: The benefit–risk profile of rivaroxaban versus warfarin for atrial fibrillation (AF) in patients with chronic kidney disease is uncertain. We compared rivaroxaban with warfarin across the range of kidney function in adults with AF. Study Design: Multicenter retrospective cohort. Setting & Participants: Adults with AF and a measure of estimated glomerular filtration rate (eGFR); using administrative data from 5 jurisdictions across Australia and Canada (2011-2018). Kidney function was categorized as eGFR ≥60, 45-59, 30-44, and